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Introduction: Palliative care is the approach to the care of patients with life-threatening illnesses. An 
important part of this is the rational use of a pharmacological approach to relieve suffering by 
addressing the symptom burden of the patient. Palliative care symptoms contribute a great deal to the 
suffering of the patient and affects quality of life. Different studies across several countries on the 
palliative care symptoms have identified common symptoms with pain being the most frequent. The 
WHO Public Health Strategy for palliative care outlines four components: policy, education, 
implementation and drug availability. These components interlink and each one affects the others. The 
drugs used for palliative care symptoms should be classified as essential medicines and be available to 
all patients who need this treatment. Factors influencing the effective pharmacological management of 
palliative care symptoms include drug availability, policy and the approach of the prescribers. Studies 
have shown that developing countries rank low in the use of the essential palliative care drugs especially 
morphine.  
Aim: The aim of this study was to describe the prevalence of palliative care symptoms and the 
prescribing and administration patterns in oncology and haematology patients at PGH, as well as 
exploring the health workers’ opinions on the pharmacological approach to these symptoms.  
Methods: A mixed method approach was used to qualitatively look at the health workers’ responses 
using inductive thematic analysis and quantitatively obtain information on palliative care symptom 
management from the health workers and patient records. 
Results: Pain was the commonest palliative care symptom identified by health workers, and evident in 
the patient records. A list of other palliative care symptoms, and the frequency at which they occurred 
was compiled in this study. The health workers highlighted drug availability, palliative care education 
and need to engage some nurses in prescribing some of the palliative care drugs. Fewer than half of the 
patient records assessed as being in need of palliative care (N = 247) were given medications from the 
recognized palliative care drug list (N = 101). 
Conclusion: This study showed that essential medicines for palliative care symptoms are not easily 
available in Zimbabwe for various reasons that include cost, policy, education and training. Pain and 
other palliative care symptoms are not adequately managed. Therefore; palliative care is not yet 
integrated into the health care system in Zimbabwe as mandated by the WHO. Recommendations to 
improve palliative care symptom treatment are suggested. 




1. Introduction   
Palliative care practice and services are an important part of public health practices and policies 
around the world; understanding how health care workers treat patients in their care can help 
explore the challenges and room for growth in local contexts. It is widely acknowledged that 
there is a need for improved palliative care services in Zimbabwe and similar Low Income 
Countries (LIC) and Low to Middle Income Countries (LMIC) contexts (1-4). The Lancet 
Commission on Palliative Care and Pain Relief showed that 25.5 of 56.2 million deaths in 2015 
were associated with serious health-related suffering and more than 80% of the 61 million 
people with conditions requiring palliative care live in LMICs (1). As is reported in the Zimbabwe 
National Palliative Care Policy (Hospaz.co.zw, 2020), in this context,  patients suffer due to 
conditions such as cancers and HIV/AIDS, which may cause premature loss of life (5).  The 
palliative care needs for Zimbabweans was estimated at 1 in 60 in a World Health Organisation 
(WHO) initiated study done in 2004 which looked at 5 countries inclusive of Zimbabwe (6). The 
purpose of this research is to better understand local palliative care practice. By better 
understanding the palliative care practice in the Zimbabwean context, health care workers’ 
actions and opinions can feed back into future policy and recommendations. 
The need for palliative care services requires robust evidence to persuade health departments 
and health care providers to meet that need and fulfil the obligation that the World Health 
Assembly (WHA) Declaration of 2014 requires of all nations that are signatories to the WHO (4). 
The Zimbabwe National Palliative Care Policy states that “operational research should be 
conducted to improve evidence for palliative care services and to identify best practice models” 
(5). As efforts to integrate palliative care into the health care system for the whole country of 
Zimbabwe are currently in the process, it would be helpful to present local evidence in order to 
strengthen its acceptance.   
In-order to establish the best practice models via research, it is necessary to build an 
appreciation of palliative care and its components. The WHO definition of palliative care states 
that “it is an approach that improves the quality of life of patients and their families facing the 
problem  associated with life-threatening illness, through the prevention and relief of suffering 
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by means of early identification and impeccable assessment and treatment of pain and other 
problems, physical, psychosocial and spiritual” (7). Pain is a common and feared symptom of 
both cancer and non-malignant life-threatening disease, (8) so pharmacological approaches to 
pain are among the priority interventions in these patients.      
Sub-Saharan Africa (SSA), which comprises many LIC and LMIC countries, has an increasing 
burden of non-communicable diseases (NCDs) including cancers and cardiovascular diseases 
which contribute to the need for palliative care in those countries.   The increase in NCDs makes 
a big contribution towards the need for palliative care. In their study, Mufunda and colleagues 
stated that the burden of disease due to NCDs “is rapidly increasing based on projections made 
from a limited number of African reports” (9). In the context of HIV illness, such as is found in 
parts of Africa, Magodoro et al report that NCD risk was higher in persons with HIV, particularly 
if these persons were older than 50 years (10). This further contributes to the need for 
palliative care. A study on palliative care in SSA focusing on Uganda, South Africa and Zimbabwe 
showed the effectiveness of palliative care services, especially in the HIV population (11). While 
the Lancet report and the Zimbabwe national palliative care policy indicate the need for pain 
relief, it is important to elicit the views of health workers, who are hands on with the patients, 
in order to come up with strong supporting information to use in advocating for essential 
palliative care medicines. Healthcare providers are important in the implementation of any new 
approach.    
A report on research into palliative care in SSA from several palliative care experts, published in 
the Lancet in 2013, proposed that research be made the fifth pillar within the WHO public 
health strategy for palliative care (3). The need to include research is necessary to allow for a 
broader evidence base from within Africa, especially for cancer palliative care due to the 
projected increase in cancer incidence in the African region, in order to  inform best practice 
(3). Evidence-based information from Africa is necessary accurately to describe palliative care 
symptomatology and its management (11). Some studies from the African context that have 
looked into the pharmacological aspects of palliative care focused on a few symptoms related 
to a limited number of conditions, i.e. HIV/AIDS or a stage of illness, namely the end of 
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life/terminal stages in palliative care (12-15).  One such example reported the study of the “use 
of sedation for the management of end-of-life shortness of breath and delirium” in a hospice in 
South Africa (15). The same study highlighted the variability that exists in the management of 
these symptoms, hence the need for further investigation (15).  
This study seeks to add to the evidence base on the current pharmacological management of 
palliative care symptoms in the African context by conducting a retrospective survey of patient 
records and obtaining feedback from some of the health workers at Parirenyatwa group of 
hospitals (PGH) in Harare, Zimbabwe. PGH is one of the few referral hospitals for haematology 
and oncology patients in Zimbabwe. Though acknowledging that all life-threatening conditions 
require palliative care, the scope of this study was limited to cancer patients, and the 
researcher took advantage of the historical evolution of palliative care within and alongside 
oncology (16) by focusing on palliative care as offered to oncology and haematology patients. 
The study examined medical records and obtained information from the health workers.  
From the palliative care definition, it is imperative that the availability and use of essential 
palliative care medicines and equipment is made a priority in the national palliative care 
policies of all countries (17). For a consensus on the essential palliative care medicines and 
equipment, a list of twenty one common palliative care symptoms was developed first by the 
IAHPC (International Association of Hospice and Palliative Care Committee) which followed by 
identifying the medications used to treat these symptoms (18). This process engaged many 
palliative care leaders from around the world (18). 
In this study, a symptom list has been adopted from the findings of Potter et al (19) so that the 
symptom burden can be correlated with the management of the palliative care patients, 
especially the prescription of medicines. This symptom list was used as it covered a wide range 
of the expected symptoms in palliative care. The list enabled health workers in this study to 
identify what they encounter most in their practice and also helped in identifying palliative care 
symptoms in the retrospective survey of patient records. The availability and use of 
pharmacologic agents for palliative care symptoms in Zimbabwe is an area which requires 
4 
 
investigation and documentation especially in the context of current efforts to include palliative 
care as part of routine patient care 
2.  Literature review 
2.1 Public Health Strategy (PHS)  
At the core of this investigation is the place of healthcare workers within the context of public 
health policy and practice. Public health is defined as the science of protecting the safety and 
improving the health of communities through education, policy-making and research for 
disease and injury prevention (20). In 2002, Sepúlveda et al. proposed that “it is essential to 
promote a public health approach in which comprehensive palliative care programs are 
integrated into the existing health systems” (21). The WHO further advocates that these 
programs are implemented in a way that is in keeping with the context of the population for 
whom they are implemented (21). This is supported by the fact that “the heterogeneity of 
palliative care populations complicates efforts to generalize from one population to another” as 
expressed by Currow and colleagues in the Journal Of Pain And Symptom Management, 2009 
(22). Quality care at end of life is a global public health problem (23, 24), and in the African 
context this is evident as many people with life-threatening illnesses do not have access to 
adequate palliative care (21). The WHO public health strategy (PHS) for palliative care 
encompasses four main domains: Policy, Drug Availability, Education and Implementation (25). 
Richard Harding and colleagues suggested that the PHS should have a fifth focus area of 
research activity to stimulate improvement of care (3). The importance of public health 
provision was highlighted by the United Nations’ Sustainable Development Goals (SDG). SDG 
Target 3 includes the following: “Achieve universal health coverage, including financial risk 
protection, access to quality essential health-care services and access to safe, effective, quality 
and affordable essential medicines and vaccines for all” (26). Countries cannot meet Sustainable 
Development Goal (SDG) Target 3.8 on Universal Health Coverage (UHC) without including 




Figure 1: WHO Public Health Model (25) 
 
As can be seen in Figure 1: WHO Public Health Model, underneath the umbrella of policy, 
according to education, drug availability and implementation of standards of practice, 
healthcare practitioners bridge the gap between situation and outcomes for patients. All of the 
elements in the diagram must be held together for successful palliative care approaches, and 
the purpose of the study is to see how they can be supported through research. This study 
focuses on one of the domains of the WHO PHS on palliative care (25), namely drug availability.  
Progress towards palliative care integration in Africa should examine factors influencing the 
implementation for it to be successful. The public health model gives a pictorial summary of the 
factors influencing the success of palliative care. Figure 1 above shows that adequate drug 
availability for palliative care is affected by the policy, associated education and the 
implementation of the services at all levels. These are interrelated components of the PHS 
which are mutually interdependent. Due to the interlinking of these areas of focus, it is 





As WHO continues to emphasize and encourage all countries to integrate palliative care 
services into their health system, Stjernswärd et al. argue that for the Public Health Strategies 
to work, governments must incorporate them throughout healthcare and gain acceptance by 
the communities (25). A study done in 2004 on the health seeking behaviour of HIV/AIDS 
patients in Malawi revealed that health facilities are usually the last resort for patients who 
attend the traditional healers and faith healers first (27). The health seeking behaviour of 
Zimbabweans would be likely to be similar to those of Malawians due to the two countries 
sharing borders and having similar challenges related to poverty and health care. Low income 
countries like Zimbabwe and many other African countries also face the challenge of 
distributive justice in the access to essential palliative care drugs, which in turn has 
consequences on the patients’ quality of life (28).  It is in line with this WHA 67.19 declaration 
on palliative care 2014 (29) that most governments, including Zimbabwe, are integrating 
palliative care as part of total patient care. When considering drug availability and the policies 
in place concerning controlled drugs such as opioids, it is important to also consider issues of 
accessibility and affordability, particularly within a LIC context. The WHA resolutions in 2014 
emphasized the PHS focus on drug availability by resolving to “ensure adequate supply of 
essential medicines in palliative care, avoiding shortages and to improve access and rational use 
of pain management medicines, in line with the United Nations (UN) international drug control 
conventions, as well as to update as appropriately the national essential medicines lists” (29).  
2.2 Palliative Care Symptoms in Haematology and Oncology Patients   
In the past, and even to the present day, cancer in its diversity remains a major life-threatening 
illness. In 2003, Potter et al. conducted a retrospective study in which they investigated 400 
referrals for palliative care in London, of which 95% (380) had a diagnosis of cancer (19); this 
indicates the comparative impact that public health research into the management of palliative 
cases could have in the African context. Other conditions, such as HIV/AIDS, increase the cancer 
burden within developing countries, particularly where certain cancers such as cancer of the 
cervix and lymphomas are on the rise in HIV/AIDS patients (30). Haematological malignancies 
and solid tumours require palliative care, as they are all chronic diseases which frequently 
present with distressing symptoms towards the end of the patient’s life. Oncology is 
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traditionally understood to focus on solid organ cancers, while haematology focuses on both 
benign and malignant bone marrow, lymphoreticular and blood conditions. The differentiation 
between these disciplines makes pragmatic sense, as there are distinct diagnostic and 
therapeutic differences. Palliative care management draws the two together, however, as the 
symptom burden and psychosocial and spiritual aspects are very similar, independent of the 
nature of the disease. This was affirmed by the results of a study conducted in 2008 in the 
United Kingdom (UK) which revealed that patients with haematological conditions had similar 
problems to those with solid tumours (31). These findings suggest that symptoms which 
present in palliative care seem to cut across all life-threatening illnesses, and therefore, their 
management should be part of the consideration for public health policy on palliative care. 
In a 2011 study on the prevalence and burden of palliative care symptoms in two African 
countries, Harding et al. reported that most of the cancer diagnoses in Africa are made when 
the disease has progressed beyond the stage of possible curative intervention; additionally,  
there is limited evidence from African contexts regarding the symptom burden in advanced 
cancers (32). From the various places of care in their London-based study, Potter et al.  
reported that the key palliative care symptoms are consistently reported, with the main 
symptoms being pain and weakness/fatigue (19). Harding et al.’s  2011 study in an African 
context showed a similar trend to Potter’s study, whereby “pain, lack of energy, feeling sad, 
feeling drowsy and worrying” were among the 5 most prevalent symptoms (32). Harding et al.’s 
study on “the prevalence and burden of symptoms amongst advanced cancer patients 
attending palliative care” showed that “pain and psychological symptoms were the most 
common symptoms” (32). In the 1990s it was noted that many patients with cancer or AIDS 
developed cachexia before death and about 80% of patients with upper gastrointestinal cancers 
and 60% of lung cancer patients at diagnosis have substantial weight loss (33). A South African 
study on sedation for uncontrolled symptoms in hospice care of the imminently dying revealed 
that the major symptoms were pain, nausea, dyspnoea and delirium (15). While studies may 
differ on what the commonest symptoms in palliative care are, the message which comes 
across is that patients with life-threatening illnesses experience suffering that alters their 
quality of life. Taking these studies into account, there is a gap in the literature: there is limited 
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evidence from research describing the symptomatology and management of patients with life-
threatening/life-limiting illnesses in Zimbabwe however.  
Palliative care symptoms vary according to the progression of the disease trajectory; several 
factors can influence what the patient presents with, however an overall analysis of the main 
symptoms in palliation is important in guiding provision of care and the best approach. The 
assessment tools must be user-friendly to the patient and the clinician, which will reduce the 
specific challenge of missing data especially in terminal and end of life stages (34). 
The same study by Potter et al. came up with the following twenty-seven palliative care 
symptoms as shown on Table 1 below, starting with the commonest (19), this provides a wide 
range of symptoms to act as a guide when assessing patients.  
Table 1: Palliative care symptoms listed in order from most frequently reported to least 









9. Weight loss 
10. Low mood 
11. Vomiting 






18. Sleep problems 





24. Early satiety 
25. Sweating 
26. Hiccoughs 
27. Taste change 
 
Studies conducted across different geographical and social contexts produced similar lists of 
palliative care symptoms, meaning it is equally important to consider symptom management 
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trends, and whether these are applicable to the Zimbabwean context too. It is important in 
palliative care to emphasize the fact that palliation and curative measures can go hand in hand. 
Sometimes the patient’s quality of life is not met by simply focusing on curative measures, and 
when this is not possible or not available a “nothing else can be done” attitude seems to 
overshadow even the basic approaches that can provide comfort and relief to the patient. For 
example, in the early 2000s when antiretroviral therapy (ART) was not readily available, 
patients who had AIDS-related symptoms like pain, cough, dyspnoea, diarrhoea, anorexia, 
nausea, pruritus or malaise would get little attention to relieving these symptoms (35). In the 
African context, poverty can often be a hindrance to access the curative measures of a life-
threatening illness and palliative care can still provide the comfort and relief due to the holistic 
focus on the patient’s needs.   
2.3 Pharmacological Management of Palliative Care Symptoms  
In 2007, the IAHPC produced a list of essential medicines for palliative care through an 
extensive process that was led by palliative care experts from across the world (36). The experts 
encouraged research to provide an evidence base for use of the recommended medications. In 
2013, the WHO came up with a list of 15 palliative care and pain medicines based on 11 
palliative care symptoms in advanced disease stages and end of life stage (37). According to the 
WHO, essential medicines are those that satisfy the primary health care needs of the 
population.  This study uses the palliative care medicines/drugs used to manage palliative care 
symptoms, some of which are not on the above-mentioned list as the WHO list was for a few 
symptoms.  In response to this need to effectively manage palliative care symptoms, many 
countries are now developing or adding a section on drugs used to manage palliative care 
symptoms to their existing national drug lists. As palliative care continues to grow as a specialty, 
more evidence is emerging showing the efficacy of pharmacological interventions for palliative 
care symptoms. For example, in 2015 a retrospective cohort study at a palliative care centre in 
the Netherlands showed that at the end of life most patients receive discomfort relieving drugs 
(38). A recent study conducted in 2018 provided evidence for the pharmacological approach for 
some palliative care symptoms like breathlessness, delirium, nausea and vomiting, constipation 
and respiratory secretions (39). All research efforts, including the development and 
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accumulation of further evidence based on the care of patients requiring drug treatment in 
palliative care, contributes to further improvement of care.  
In Zimbabwe, the 2015 essential drug list has a section on medicines used for pain management 
in palliative care (40). While having this section on palliative pain management is a 
commendable step, there are still important gaps which need to be considered. Areas of 
concern include the management of palliative symptoms other than pain, additional equipment 
and infrastructure for palliation, and the support and training of professionals for palliative care 
provision. There is a need, for example, for professionals who are skilled at using subcutaneous 
infusion pumps in palliative care (so-called syringe drivers). The ongoing revision and update of 
guidelines should include continuity of care, including out of hours care, advanced prescribing 
(like flexibility of dosing), continuity of supply, and urgent need provision for palliative care 
needs as they may change even after hours (41).   
A key symptom in the literature, which will be a central focus of this study, is the need to 
manage and control pain, as it is often what the patient often presents with. Several studies 
have been conducted from different groups of patients at different stages of illnesses looking at 
the physiologic control of pain (42). Adequate pain assessment in palliative care allows for best 
practice in the provision of care (43). According to WHO guidelines, the analgesic step ladder 




Figure 2: The WHO Analgesic Step Ladder 
There are three main principles of the WHO analgesic step ladder, namely “By the clock, by the 
mouth and by the ladder” (45). “By the clock” means that analgesic drugs should be 
administered regularly on a fixed schedule depending on the need of the patient and the 
conditions and the pharmacological properties for the agent. “By the mouth” means that oral 
administration is preferred in every circumstance unless the patient is unable to swallow or is 
vomiting. “By the ladder” means that the principles of the WHO analgesic pain ladder be 
followed with titration of the dose to meet the needs of the patient and the condition.  The 
analgesic step ladder approach should be used starting with simple analgesics such as 
paracetamol for mild pain, then moderate analgesics or mild opioids such as tramadol and 
codeine phosphate for moderate pain, followed by strong opioids like morphine for severe pain 
(46). At each level of pain control, simple analgesics and other co-analgesics like amitriptyline 
can be given in addition to the pain medications for that level depending on the type of pain 
the patient is having. This analgesic step ladder has undergone several modifications over the 
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years to meet the needs for acute and non-cancer pain control as well as reviewing approaches 
to chronic pain management (44). These modifications have resulted in the addition of a fourth 
step which encompasses: nerve block, epidurals, patient-controlled analgesia (PCA) pump, 
neurolytic block therapy and spinal stimulators (46). The basic WHO analgesic step ladder still 
remains an important template in coming up with practical pain management protocols (44).  
Palliative care medicines/drugs in this study refer to the medicines used to manage palliative 
care symptoms potentially without randomised clinical trials for each symptom to produce 
supporting evidence for the drug used. The distribution of pain medications among all the 
countries revealed that Africa had only 0.8% of the share as reported in a study in 2009 on the 
global distribution of pain medication especially morphine (47). The distribution of these 
medications is indirectly made worse by certain attitudes towards them for example 
opiophobia. Opiophobia occurs when people are more concerned about the side effects of the 
opioid drugs than appreciative of the medical benefits in controlling pain, especially in 
addressing chronic pain (48). The fears and myths especially on the use of opioids (morphine 
being the prototype) in managing pain in patients with life-threatening illnesses contribute to 
the barrier to effective pain control (49).  One of the myths in palliative care is the use of 
injection pethidine as needed whenever patient complains of cancer pain (49). The fact is that, 
unlike post-surgical pain, cancer pain or chronic pain is not self-limiting nor is it likely to recede 
spontaneously, but instead it is more likely to increase in intensity and severity (49) hence this 
discourages pethidine use because of its untoward effects even though it is an opioid. It has 
been verified that pethidine metabolite norpethidine accumulates in the body with repeated 
use of pethidine leading to untoward effects such as convulsions especially in the elderly. 
As palliative care is a field in its infancy in most developing countries, many gaps exist in all 
aspects of palliative care, including availability of essential palliative care medications in their 
different forms. This also calls for continued research at all levels within the developing world if 
palliative care services have to be well integrated into the health care system.  
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2.4 Prescribing for Palliative Care Symptoms    
There is no local data yet from Zimbabwe to demonstrate the prescription of the listed essential 
palliative care medicines, especially opioid analgesics, by clinicians, or to discuss the trends that 
govern these drugs’ prescription and use. Prescribing and administration of drugs in palliative 
care is sometimes ethically difficult due to several reasons for example the timing and selection 
of outcome measures and the complexity of medication regime at home (50, 51). The 
prescription of morphine for patients near death and most of the other ethically difficult 
reasons encountered in palliative care drug prescribing and administration still require 
extensive discussions as well as support from research. Anderson argues that “applying the 
principle of double effect to end-of-life issues perpetuates the myth that opioid use at end of 
life causes respiratory depression and results in the undertreatment of physical suffering at the 
end of life” (51). Focusing on the local context, efforts are being made understanding drug 
prescription and administration, especially through collaboration with non-governmental 
organizations (NGOs) like Island Hospice, a WHO-recognized palliative care demonstration 
centre that mentors and trains health workers at all levels in palliative care. For particular 
interest in this study, the NGO trains medical students and specializing doctors on the 
pharmacological approaches to palliative care symptoms, as well as community health workers 
who are important in the supervision of the patients taking the medications (52).  
While the ethical principles of autonomy, beneficence, non-maleficence, and justice apply 
across all health practices, there may still be concern and lack of assuredness for practitioners, 
particularly concerning palliative sedation of terminal patients. Lewis et al.  stated in 2010 that 
the “fear of overuse, misuse, abuse and addiction in prescribing opioid analgesics in patients 
with chronic pain is one of the major causes of opioid phobia among physicians” (53). Walsh 
and Hauser stated that in palliative sedation, certain considerations such as which practitioners 
should be responsible, and the restriction of prescription and administration to licensed 
palliative medicine specialists, are important ethical considerations (54). Another important 
consideration when discussing the administration and prescription of important drugs for 
palliative care patients is which health workers are involved in the process. The health workers 
in this study included nurses, doctors and pharmacists. The role of pharmacists in palliative care 
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is more and more being recognized as the inter-disciplinary and multi-disciplinary nature of 
palliative care continues to unfold (55).  In a 1996 study by Drummond et al. indicated there 
was lack of consistency in the use of medicines that are combined in syringe drivers in palliative 
care (56). Different understanding and practices influence the use of syringe drivers; in some 
cases, availability may be a key factor in the lack of use. A follow-up study on those using this 
method would give a give a better evaluation of the uptake of this care provision in palliative 
care, especially at end of life.  
Prescribing practices in palliative care, especially in developing and third world countries like 
Zimbabwe, may also be affected by lack of resources, the application of a health system 
paradigm from wealthy contexts (where current evidence comes from), and a universal fear of 
death and seeking of cure at all costs. The WHO, through the IAHPC, has developed an essential 
palliative care list which can be used as a model for countries to come up with their own 
national palliative care lists that meet local needs and take into account local resources, 
especially developing countries like Zimbabwe where there is limited availability of opioid 
analgesics and other palliative medications (37). Another area of concern is the use of 
combination drugs especially in chronic pain management for example a study done in South 
Africa (2016) by Truter “concluded that, first, generic substitution had an impact on prescribing 
patterns and, second, that more studies are needed to quantify combination analgesic and 
specifically meprobamate-containing analgesic prescribing” (57). Local national palliative care 





3. Rationale   
Palliative care is about providing quality of life to people with life-threatening illnesses. For this 
to be achieved, a holistic approach is required in their care, including ensuring that the 
medicines/drugs needed are available and that prescribers follow best practices. This includes 
the excellent assessment and management of symptoms as envisaged in the WHO definition of 
palliative care, which in turn requires appropriate use of medication, that these drugs are 
available for use and that the supply is ensured. The palliative care symptom burden as raised 
by the patients or their care givers is essential evidence in advocating for palliative care. It is 
therefore important to research and review the local evidence of the current pharmacological 
management of palliative care symptoms in Zimbabwe, in order to establish a baseline from 
which the need for change can be evaluated. As palliative care is a new specialty, research 
coming from all countries, developed and developing, is an essential component in its provision 
and uptake by the patients and the health workers. The factors influencing the availability and 
uptake of palliative care drugs in each African country may overlap or be totally unique to each 
country. Results of this study and other similar research are intended to provide policy makers 
with an evidence base to support critical decisions to do with palliative care.  
 
It is important to conduct this study to provide a baseline for the Zimbabwean context for 
comparison and development to improve policy and practice, and ultimately contribute to 
better patient care, the achievement of the sustainable development goals and universal health 
coverage throughout the trajectory of life.  
3.1 Aim:   
The aim of this study was to describe the prevalence of palliative care symptoms and the 
prescribing and administration patterns in oncology and haematology patients at PGH, as well 
as exploring the health workers’ opinions on the pharmacological approach to these symptoms.  
3.2 Objectives:  
1. To review the palliative care symptoms in haematology and oncology patients at PGH. 
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2. To describe patterns of drug prescription and administration for palliative care 
symptoms at PGH. 






4. Methodology  
4.1 Study Design  
The study employed a mixed methods research (MMR) approach (58) using both qualitative 
and quantitative methods. Research methodology is developing and current evidence shows 
that combining different research methods gives an advantage of making use of the strengths 
of each method resulting in a stronger study. In this study, the qualitative aspect involved the 
use of a questionnaire which the health workers filled in, while the quantitative component of 
the study was a systematic document review methodology of patient records from 2017 until 
the required sample size was reached. Data collection was done in October 2018 and the most 
recent medical records to be accessed were of the year before (2017), since written records are 
scanned and stored into a system monitored by the medical records department. The 
department explained that records from the current year (2018) were still being uploaded 
hence they recommended use of 2017.  
 
The patient records and health worker responses were considered adequate data sources to 
obtain the record of the pharmacological management of the palliative care symptom burden 
for the purposes of this project. Investigating the patient experience of the illness was beyond 
the scope of this study.  
 
4.2 Study Sites  
The study was conducted at PGH located in Harare. This is one of the main referral hospitals in 
Zimbabwe and serves as one of the few referral hospitals for haematology and oncology 
patients in the country. The haematology and oncology departments of PGH were used as the 
study sites, and the records department was used to get access to patient notes and 
information. The Zimbabwe national cancer registry is situated at the PGH complex and most of 




4.3 Study Population  
The study population included 12 doctors and 14 nurses working in the haematology and 
oncology departments and 2 pharmacists at PGH. All the participants agreed to take part in the 
study. Records of admitted (in-patients) haematology and oncology patients seen in 2017 
provided the required sample for the quantitative analysis. If there were any re-admissions of 
the same patient encountered during the sequential extraction from admission books these 
were not taken. The rest of admissions of the same patient or other patients within the year 
were not included if falling outside the required sample selection criteria and after the required 
sample had been obtained. In line with the WHO definition and principles of palliative care 
which emphasizes that palliative care begins from the diagnosis of a life-threatening illness the 
study made the assumption that all the oncology and haematology patient records therefore 
would fit under palliative care and most of the diagnosis in these fields were assumed to be life-
threatening (21).  
 
Inclusion criteria:  
All doctors, nurses and pharmacists working in haematology and oncology departments at PGH, 
who agreed to take part, regardless of their duration of service in these departments were 
included in the study. Only information extracted from admitted patient notes/records for 2017 
was used.  
 
Exclusion criteria:  
All the doctors, nurses and pharmacists not working in the haematology and oncology 
departments were not included in the study. Haematology and oncology in-patient 
notes/records before and after 2017 were not used and readmissions of same patient were not 




4.4 Sampling  
4.4.1 Patient records 
For the purpose of this study, convenience sampling was conducted, reviewing the records of 
patients who were seen at PGH in 2017. Convenience sampling is a non-random sampling 
technique where members of the target population meet certain practical criteria (60).  
 
The sample size required for the study was calculated as follows: the required sample size of 
the study participants was determined by Dobson's (1984) single population proportion formula 
using the assumptions of z, standardised normal distribution value for the 95% Confidence 
Interval, which is 1,96, p=0,80, an estimated proportion of cancer patients whose pain was 
effectively controlled by using the WHO recommended analgesic ladder guideline (Soares, 





A minimum sample size of 246 complete patient records was therefore required. The total 
number of 247 patient records was therefore obtained using convenience sampling, by means 
of accessing the required patient records using the hospital record system. This was done first 
by looking up successive admission hospital numbers up to 123 patients in the record book of 
ward C3 (haematology) and up to 124 from A6 (oncology) admitted in 2017 and then obtaining 
the records from the computer. The total number of records (247) required was reached within 
the period of January to March 2017. 
 
4.4.2 Health workers 
As mentioned earlier, convenience sampling is a non-random sampling technique where 
members of the target population meet certain practical criteria (60), such as patients in given 
wards, or health workers who operate within a given context. In this study, it was therefore 
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necessary to select health workers who possess the required criteria (working in the 
haematology and oncology departments and pharmacists at PGH), from among the rest of the 
health workers at the hospital. In qualitative studies, data analysis often takes place alongside 
data collection to allow questions to be refined and new avenues of inquiry to develop (62). 
During this process, the researcher conducts inductive thematic analysis to expose and explore 
categories, themes and subthemes as they emerged from the data. In the case of this study, the 
data relating to the health workers at the hospital was collected using a questionnaire and was 
halted once data saturation was reached.  
 
4.5 Data Collection Tools and Processes 
A questionnaire was used to collect information from the health workers. The questionnaire 
was administered in English to the health workers because English is the official language at 
work. With the permission of those in charge of the departments, information about the study 
was shared with small groups of doctors, nurses and pharmacists in both haematology and 
oncology departments. In the same meetings, the staff was informed that the researcher or 
research assistant would approach them with a consent form and questionnaire within the 
following week. It was anticipated that the questionnaire would take some time to complete, 
for which the participant was informed in the information sheet and one day was suggested as 
a helpful turnaround time. The anticipated turnaround time to get the questionnaire back 
seemed adequate for most of the research participants, who went through the information 
sheet in the morning when they reported for duty, and who were given the questionnaire at 
the same time. The participants then filled in the questionnaire during their tea or lunch break, 
submitting it to the researcher the following morning.  
 
For convenience and quick identification of study participants, an oncology nurse working in 
the haematology ward was trained as the research assistant. The researcher elected to train an 
oncology nurse in the task, as their prior training as oncology nurses covered medical ethics and 
confidentiality. This knowledge and skill is transferable to medical research where autonomy 
and confidentiality are important. The research assistant’s participation was voluntary and 
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there was no coercion. The researcher trained the research assistant, and supervised the survey 
distribution activities of the research assistant; the researcher then collated and filed the 
survey questionnaire results before analysis, ensuring that the assistant had conducted the 
process correctly before continuing with data analysis.  
 
When the health workers were surveyed, the research team ensured that they understood the 
purpose and aims of the research study, and agreed to participate. Each participant was given 
an information sheet first explaining what the study was about, followed by signing the consent 
form and agreeing to the proposed submission timeline mentioned above of 24 hours. The 
researcher assigned each participant survey document a number in ascending order, starting 
from one, before the research assistant distributed the questionnaires amongst the 
participants. This was done so as to ensure the participants’ confidentiality and avoid bias on 
the part of the researcher when analysing the survey results.  
 
For the patient notes/records, the researcher arranged specific days and times with the records 
department to retrieve the required patient notes and fill in the necessary information in on 
the survey sheet. All the hand-written patient records at PGH are scanned and stored into a 
computerised system; this allows researchers with permission to log in with assistance from the 
records staff, conduct their research activities, and log out before they leave. Information was 
serially extracted from the patient records until the required sample size was reached, a 
process that took five working days for the researcher to complete, doing two hours every day. 
The survey areas for the quantitative part of the study using the patient records are listed at 
the end of Appendix 2, and the palliative care symptom list in Table 1 was used as a guide to 
identify the palliative care symptoms, however other symptoms not included on the table were 
also identified and analysed separately.  
 
4.6 Data Analysis  
The data obtained was transcribed by the researcher from the questionnaire responses into an 
electronic format for the purpose of analysis. Quantitative data was summarized in tables and 
22 
 
graphs, using short descriptions while the qualitative part was progressively analysed using 
inductive thematic analysis. A 16 gigabyte USB memory stick was used as an intermediate 
storage device from the computer, while every second or third day all the information was 
saved on a one terabyte external hard drive which was kept in a lockable drawer in order to 
keep the data secure and confidential. The audit from the patient records was entered into 
excel spreadsheets and analysed using the Social Package For Social Sciences (SPSS). 
Conducting the thematic analysis of the qualitative data was guided by the steps offered by 
Maguire M and Delahunt (2017) (63) and the researcher made a comprehensive critical analysis 
of the source data following Braun and Clarke (2006)’s description of thematic analysis (64) as 
listed below:   
Step 1: Become familiar with the data, 
Step 2: Generate initial codes, 
Step 3: Search for themes, 
Step 4: Review themes, 
Step 5: Define themes, 
Step 6: Write-up. 
 
4.7 Validity and Reliability  
Blanche et al in 2006 stated that “validity shows how sound the research findings are while 
reliability brings out how well the data can be reproduced”  (65). A pilot study was used to test 
the viability of the questionnaire as a reliable and valid research instrument. As part of this trial, 
three senior health workers conveniently picked first from haematology, then from oncology 
and third from pharmacy department completed the questionnaire and gave the 
recommendation and suggestion to keep the questionnaire as open as possible. Based on these 
three responses, a few questions were refined or added, resulting in the final questionnaire 
which was later used to conduct the research. From this qualitative part of the study, the pilot 
showed that the health workers in the chosen departments were eager and provided the 
information; the fact that they took care of patients with palliative care symptoms in their work 
made the study more valid and reliable as they gave responses from their palliative care 
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experience. As for the patient records, the validity and reliability of the information that was 
extracted was tested by initially going through the first 10 oncology and haematology records 
comparing these data points with the disclosed objectives of the study. The researcher noted 
that the intentions of the study were coming out and hence continued with the rest of the 
records. In order to make sure the required health records were looked at during the survey, 
the researcher entered each new record using the hospital number and admission date into a 
note book and extracted responses to all the survey areas for each record before moving to the 
next.  
 
4.8 Ethical Considerations  
Permission to conduct the study was obtained from the two research ethics committees: UCT 
Human Research Ethics Committee (HREC) in line with the MPhil requirements and Medical 
Research Council of Zimbabwe (MRCZ), as the research was to be conducted in Zimbabwe. 
Copies of the permission to conduct the study from both UCT HREC and MRCZ are included at 
the end of the dissertation in the appendices. The clinical director of PGH and the heads of the 
respective departments were approached and given the proposal with the authorization from 
both research committees before commencing the study. For the questionnaire targeting 
health workers, informed consent was first obtained from the participants. Participants’ 
confidentiality was maintained by using a coding system, where numbers were used instead of 
names. The same was applied to the patient records where instead of using patient names, the 
hospital numbers were used and coded with numbers in increasing order until the target 
number was reached. Participation in the study was voluntary and there was no barrier to 
participation or withdrawal. Participants were fully informed and were also informed that their 
participation was voluntary, and that they could withdraw at any time without explanation or 
prejudice. 
  
4.9 Work Plan  
The researcher had to meet the financial costs especially towards payment for the research 
assistant and the cost of research data collection stationery. The researcher sourced the 
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funding for the study from friends who support palliative care initiatives and from part-time 
work. The timeline of the study had to fit into the UCT MPhil in palliative care program.   
 
4.10 Dissemination of Findings  
The research findings will be shared with PGH, particularly the staff in the haematology, 
oncology and pharmacy departments, as they comprise the main participants. The study will 
also be disseminated to the Zimbabwean Ministry of Health taskforce that is dealing with the 
palliative care integration mandate. Conferences and seminars will be used as well to 
disseminate the findings whenever there is an opportunity to do so. Finally, with the 
supervisor’s guidance an abstract of the study will be published in a recommended journal. A 
full article will be submitted for publication in a palliative care journal within one year of 
















5. Results  
5.1 Questionnaire responses  
Almost all of the health workers were senior cadres in their respective professions (doctors, 
nurses and pharmacists) evidenced by 10 of the doctors having more than 5 years’ experience 
and 12 nurses with more than 5 years; the pharmacists’ years of experience were not stated. 
The nurses and doctors were the majority of the health workers who participated in the study, 
with 50% and 43% respectively while pharmacists were the minority, at 7%. Table 2 summarizes 
the characteristics of health workers who filled in the questionnaire for the study.  
 




Less than 5 years’ experience 
5 - 10 years’ experience 
More than 10 years’ experience  
Nurses 
Less than 5 years’ experience 
5 - 10 years’ experience  













Six (21%) of the health workers, made up of two nurses and four doctors, said they use some 
form of symptom assessment method/tool in managing palliative care symptoms. The tools 
mentioned by these six participants included the pain scale, objective scoring, staging, a 
symptom assessment sheet and common toxicity criteria. No validated tools like the Integrated 
Palliative care Outcome Scale (IPOS) or Edmonton Symptom Assessment Scale (ESAS) were 
mentioned. The 27 palliative care symptoms listed on the questionnaire were selected by the 
health workers with differing frequencies. While some symptoms were commonly documented 





Table 3: Palliative care symptoms perceived by health workers in haematology and oncology 
departments 
Symptom Number of health workers 







Sleep problems  
Anxiety  
Weakness 













































































Fifteen health workers, made up of 11 doctors and four nurses out of the 28 health workers, 
responded that they prescribe palliative care medications; of these practitioners, nine said they 
consult the Essential Drug List of Zimbabwe (EDLIZ). Eleven participants responded that they 
use other references as a guide when prescribing for palliative care symptoms, with the 
following frequency:  
• British National Formulary (BNF) – three health workers, 
• UpToDate – two practitioners,  
• National Comprehensive Cancer Network (NCCN) – two practitioners,  
• Nursing drug guide – two practitioners, and 
• Medscape – one practitioner. 
In addition to this, one health worker said that he or she asked advice from senior colleagues as 
a method of informing prescribing for palliative care treatments. 
 
Ten of the health workers, made up of two pharmacists and eight nurses responded that they 
dispense medication, and six nurses and 12 doctors responded that they do not dispense. Eight 
out of the ten who dispense medication highlighted that palliative care medications in their 
stock are inadequate, while one respondent said the stock is adequate.  
 
Eighteen health workers, made up of the 10 who said they dispense drugs and eight others 
from those who said they do not dispense, responded to question 11 on the availability of 
essential palliative care drugs. The participants were required to rate the availability of certain 
essential drugs as never, sometimes or always available. Their response is summarized on figure 
3 below showing oral morphine as the most available according to these health workers. Most 
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Essential palliative drug available
Never Sometimes Always
 
Figure 3 Availability of the drugs used by 18 health workers for palliative care symptoms 
Key: IM-intramuscular, IV-intravenous, AMT-amitriptyline 
Figure 4 below; shows the medications used for pain management by the health workers. For 
mild pain, 24 (85%) of the health workers use paracetamol, while a few also use other simple 
analgesics such as non-steroidal anti-inflammatory drugs (NSAIDs) and aspirin. The health 
workers listed different drugs for moderate pain which included tramadol and codeine and 
paracetamol combinations together with some co-analgesics such as amitriptyline. From the 
doctors and nurses 22 (78%) said that morphine was the drug of choice for severe pain and four 



















































































































Level of pain and drugs used
 
Figure 4: Palliative care drugs used for different pain levels by the health workers 
Key: PCpCM: paracetamol/codeine phosphate/caffeine/meprobamate, 
PCp:paracetamol/codeine phosphate, TP: tramadol/paracetamol 
For the management of morphine side effects, 16 health workers (12 doctors and four nurses) 
reported constipation, which they treated using the following drugs according to frequency: 
• bisacodyl – 13 health workers,  
• senna – one participant,  
• glycerine suppository – one participant, 
• and liquid paraffin – 10 health workers.  
Nausea and vomiting were highlighted by 10 participants (eight doctors and two nurses), and 
the practitioners used the following drugs to combat this symptom:  
• metoclopramide – eight participants,  
• ondansetron – nine participants, and  
• polanestron– one health worker.  
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Three participants mentioned said dry mouth as a symptom, which they managed using ice 
cubes and plenty of fluids. One participant reported respiratory depression, for which they use 
oxygen, and one reported pruritis, for which they use chlorpheniramine. 
Twenty-six of the health workers (12 doctors and 14 nurses) mentioned the following 
adjuvant/co-analgesic drugs for palliative care:  
• dexamethasone -22,  
• prednisolone – 21,  
• amitriptyline – 21,  
• gabapentin – 10,  
• pregabalin – 11,  
• carbamazepine -7,  
• diclofenac, co-codamol, celecoxib and Indocin – 1. 
Twenty health workers, noted that palliative care symptoms are not adequately controlled and 
the reasons for this was given in the subsequent questions which were qualitatively analysed 
below.  
The health workers gave a long list of other palliative care symptoms besides pain, similar to 
the list provided earlier on Table 3. Only four of the listed symptoms were given corresponding 
drugs as illustrated on Table 4 below:   
Table 4: Symptoms with corresponding drugs 
Symptom Corresponding drugs 










5.1.1 Inductive analysis of the health worker responses  
The qualitative aspects of the health workers’ responses are presented here using inductive 
thematic analysis. Questions 17,18,19 and 20 of the questionnaire are presented together in 
the analysis. The analysis was done using Braun and Clarke (2006)’s 6 pack (64) as alluded to 
earlier under methodology:  
Step 1: Becoming familiar with the data. 
The health workers who said the palliative care symptoms are inadequately controlled with the 
drugs used gave a number of reasons for it. The erratic supply of drugs and the fact that 
medications are not enough as well as the supply which is outweighed by demand are some of 
the reasons for the inadequacy of drugs. They also highlighted that shortage and high cost of 
drugs as well as cultural reasons, problems for which there are no medications and issues of 
compliance as reasons for inadequate control of Palliative Care (PC) symptoms. Unavailability of 
the ideal drug and the right route for the drugs contribute in not controlling PC symptoms. The 
constraints in prescribing palliative care drugs raised were mostly similar to the reasons given 
for the inadequate supply of drugs with some additions being the knowledge deficit among 
health workers on palliative care, compliance issues and few prescribers (mainly doctors). 
Recommendations and any other comments to do with pharmacological management of 
palliative care symptoms can be categorized into ensuring better supply of medications, 
education and training of health workers and patients and advocacy and policy issues. This data 




Step 2: Generating initial codes and Step 3: Search for themes  
This process is shown in Table 5 below. 
 




Poor drug supply 
Shortage of drugs 
Drugs not accessible 
Drugs not available 
No alternative drugs 
Availability of drugs 
Accessibility 
 
Cost of drugs are high 
Poverty 
Financial constraints 
Provide free drugs 
Affordability of drugs 
Provision of free drugs 
Advocacy 
 
Cultural reasons affect taking of drugs 
Compliance issues on the patients 
Patients with issues not requiring 
medications 
Patient have their own perceptions 
Patients’ distress and discomfort 
Culture 




Lack of authority to prescribe morphine 
Nurses not prescribing drugs 
Laws that are in place for prescribing 
Pharmacists should be allowed to give 
medicines for palliative care symptoms. 




Educate health workers and patients on 
palliative care. 
PC drug formulary  
PC specialists are needed 








As shown on the table, the participants raised several issues to do with the pharmacological 
management of palliative care symptoms. Some of the highlights from the responses are: “the 
drugs are generally not available, so patients and families get prescriptions to look around and 
most do not afford to by the drugs anyway”, “this is a complex issue, even the patients’ 
understanding, compliance and other psychological issues contribute”, “prescribing is only done 
by doctors here, and sometimes there is no doctor nearby”, “it’s hard to implement something 
without appreciating its value first, there is need to educate doctors, nurses and pharmacists on 
palliative care first”. 
Step 4: Reviewing themes 
The themes obtained in Step 3 were reviewed using the initial responses of the health workers 













Step 5: Defining and naming themes 
This is the final refinement of the themes and the aim is ‘to identify the essence of what each 
theme is about’ (65). A thematic map illustrating the relationships between the themes (66) is 
given in Figure 4 below. The main themes were obtained by following common threads in the 
health workers responses and main areas/topics under the overall theme. 




Cost Supply      Prescribing Laws   Patients      Health Professionals Compliance 
Culture 
Free drugs         nurse prescribing  PC formulary  MDTs Perceptions   Distress 
Figure 4: Thematic map with the final themes and how they interlink 
 
Step 6: Write-up 
This is continuation of the write-up started, now addresses each theme and provides conclusion 
to the thematic analysis showing how it has responded to the research objective on the 
opinions of health workers on the pharmacological management of palliative care symptoms. 
5.1.2 Reviewing Key Themes 
In this section, key themes that arose from the questionnaire analysis will be discussed in more detail. 
 
Theme: Palliative care drug availability 
The cost of the drugs, their supply and the need for free drugs are subthemes under the 
availability of drugs. This theme came up several times from the responses of the health 
workers; they may have expressed this theme differently, but the core idea was to do with 
drugs not being available. Some of the phrases from the health workers were: “the supply of 
drugs is very erratic………patients cannot afford to buy the drugs as they are too 
expensive……the government should make palliative care drugs free.” 
Theme: Policy factors 
Suggestions to have nurses to prescribe palliative care drugs came out in the responses with 
some saying “nurses should prescribe morphine” and others saying “nurses should prescribe 
where the doctors are not present”. Some responses which relate to policy issues highlighted 
the need to allow pharmacists to dispense drugs for chronic illnesses to patients with no 




Theme: Training and Education 
The need for palliative care training in general for healthcare workers, especially nurses and 
doctors, was raised repeatedly with statements like “doctors and nurses fear increasing 
medication for managing pain because of palliative care ignorance……train nurses and 
doctors on the importance of managing palliative care symptoms”. Health education of 
patients and their caregivers on palliative care was raised as well as the need for multi-
disciplinary teams (MDTs) at hospitals to ensure palliative care provision. A palliative care drug 
formulary to guide the health workers was suggested by some of the respondents. 
Theme: Patient Factors 
Some of the responses were specifically directed towards the patients with statements like 
“patients are not compliant to the medications……due to cultural reasons some patients do not 
want to take their pain medications…...patients have certain perceptions about medications”. 
These and the need to educate patients and families was highlighted. 
 
 
5.2  Findings from the patient medical records survey 
A total of 247 patient records from haematology and oncology wards, of patients admitted in 
2017 (January to March) were surveyed to extract the required information. The sample size 
corresponded with the statistical calculation described in the methods section. 
 
Table 6: Demographic characteristics of patients whose records were reviewed (N = 247) 
Sex 
              Female  




Age group in years 
      10-30 






       51-70 
        71 + 
Median age (Q1; Q3)   




46 (34; 60) 
46.5 
 
A range of oncology and haematology diagnoses were obtained from the patient records. Of 
note, cervical cancer had the highest frequency, at 19% of the records, followed by lymphoma 
at 15%. Besides having a cancer or haematology diagnosis, other comorbidities were also 
obtained in many of the patient records, with HIV/AIDS as the most common comorbidity, 
appearing in 43 (17%) of the records; the second-most common comorbidity was hypertension 
(11%). 
Out of the 247 medical records reviewed, 52% of the records did not have any symptoms 
recorded on them as depicted in the pie chart – Figure 6.  
 
Figure 5: Number of patient records with and without palliative care symptoms recorded 
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The 52% of medical records that did not have any documented symptoms had no explanations 
to why there was no symptom documented.  
Of the 119 medical records that had symptoms recorded, these varied; certain symptoms like 
pain were documented in many of the records while other symptoms were less frequently 
documented. Some of the records had more than one symptom recorded, and others had a 
single symptom noted. Table 7 below gives the summary of the symptoms obtained from the 









Table 7: Palliative care symptoms from PGH oncology and haematology health records 






































(septic wounds), cachexia 
Dysphagia, palpitations 
Urinary problems, Loose 
stool 
Nausea, Sleep problems 
(insomnia), dizziness, 
restlessness, pallor, 
secretions, visual problems, 
dehydration 































While the list from Potter et al. referenced in Table 1 was used to identify symptoms from the 
patient records, there were a few symptoms obtained from the records that are not on Table 1, 
which have been  added to table 7 above, namely: loss of appetite, headache, cachexia, 
palpitations, dehydration, visual problems, secretions, pallor, restlessness, dizziness, hearing 
problems and faecal incontinence.  
Drugs used for palliative care symptoms were prescribed in 130 (53%) medical records while 
117 (47%) records did not have any of these drugs prescribed. Of the 130 records with palliative 
care drugs prescribed, some drugs were prescribed singly, while others were prescribed in 
combination with other drugs. Some drugs, like morphine and paracetamol, were prescribed 
more than others. Not all prescribed palliative care drugs were administered to the patients as 
shown in Table 8 below comparing what was prescribed and administered.  
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Table 8: Drugs prescribed for palliative care symptoms and administered 



































































A drug written in the medical record was counted as a prescription, and which if administered 
would show on the drug chart that it has been administered by the presence of the nurse’s 
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signature or initials and this study therefore concluded that the drug was both prescribed and 
administered. If the drug was not received, the drug chart had o/s (out of stock) or absent, 
hence the conclusion that the drug was not administered.  
A general trend that patients do not get all the drugs prescribed was observed. Any 
documented drugs prescribed as ‘whenever necessary’ aimed at managing palliative care 
symptoms were included in the study. Drugs were prescribed on different days for the 
admission duration and there were no repeat prescriptions of the same drug within the 
admission period. 
Of the 130 oncology and haematology records which had drugs prescribed, some had other 
drugs prescribed as well, but as they were not written on the drug administration chart, the 
researcher could not deduce whether they were administered or not. These other prescribed 




Figure 6: Other prescribed drugs not on the drug administration chart 








The aim of this study was to describe the prevalence of palliative care symptoms in oncology 
and haematology patients at PGH, alongside the drugs and administrative processes for 
managing their symptoms. As discussed earlier, a mixed method approach involving both 
quantitative and qualitative methodology was chosen in this study to provide robust evidence 
of the pharmacological management of palliative care problems in the research context. Doyle 
et al showed that mixed methods provide a more complete and comprehensive picture of the 
research, which allows for generation of a hypothesis at the end which can be tested and 
followed up in future studies (67). In this study, in-depth information regarding the 
pharmacological management of palliative care symptoms was obtained and a hypothesis that 
clinician prescribing in Zimbabwe for palliative care symptoms is influenced by a number of 
factors, the 2 commonest being palliative care drug availability and palliative care knowledge of 
the prescribers was generated. A review and description of the management of palliative care 
symptoms was provided as well as exploration of the health workers’ opinions. This section will 
review the findings and explore their implications on the policy and practice of managing 
palliative care symptoms at PGH. 
6.1 Symptoms and their management 
 
The main objective of this study was to look at the palliative care symptoms and how they are 
managed pharmacologically. This section will focus on the symptoms and how health care 
workers managed them. The researcher made the assumption that haematology and oncology 
problems fall under serious health related suffering which fits within the global consensus 




6.1.1 Documentation of symptoms 
 
The first interesting aspect from reviewing the medical records was that the medical records 
survey showed that about half (52%) of the records did not have any symptoms documented. It 
is rare that oncology and haematology patients do not show any symptoms given the chronic 
nature of most of their illnesses, so this finding highlights potential areas for improvement in 
process, particularly in documentation of symptoms. There are several reasons that so many 
patient records did not have symptoms recorded, including early stage or curative patients 
being included in the cohort, or that these patients' symptoms were all controlled, or that 
potentially it was a result of unreliable documentation on the health workers’ part. This finding 
can also be explained by the fact that the symptoms perceived as important by the doctor are 
the ones which will be reflected on the medical record which is one of the several reasons 
raised in an article by  Strömgren, Grønvold, Pedersen, Olsen and Sjogren on the 
symptomatology of palliative care (69). The researcher can make inferences based on these 
records with no symptoms: perhaps the clinician was very busy and had no time to write down 
the findings, or as stated above the patient did not present with any symptoms but simply came 
for treatment of their chronic illness (70, 71). It is however not within this study’s objectives to 
analyse the reasons for non-documentation of symptoms (whether for curative or chronic 
illnesses) on patient records, but this finding may still guide recommendations on improving 
documentation by the health workers. For example, if all the sections on the patient form are 
mandatory, the patient records would clearly show if no symptom was present, rather than 
that the health worker may not have noted it. 
 
6.1.2 Symptoms and the drugs used to manage them 
 
As mentioned in the results section, only four symptoms out of the 20 listed by health workers 
were listed with the drugs that were used to manage them (namely nausea and vomiting, 
constipation, bleeding and swelling), while the remaining sixteen symptoms were listed without 
recording a drug or treatment. This is striking, especially for research investigating the use of 
drugs to treat palliative care patients’ symptoms. One possible reason that the health workers 
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did not list the medications used for many of the symptoms might mean that perhaps they did 
not find the symptoms significant; however, there may be other explanations which would 
require more research to elicit. The patient records showed that many patients did not get the 
drugs for the palliative care symptoms they presented with for example 91 patients had 
morphine prescribed and only 61 received the drug, this could be due to the reasons given by 
the health workers to do with challenges of access to free or reduced-price palliative care drugs 
to improve their use. There is a close link between the cost of the drugs and the number of 
patients who afford to get the drugs, which will be discussed shortly. 
 






Pain emerged as the commonest palliative care symptom in this study, this corresponds with 
previous studies on palliative care symptomatology. From the patient records, pain was the 
commonest symptom observed, at 105 (48.8%) of the records, and the main drugs prescribed 
for pain were paracetamol and morphine but only 37 and 61 patients were administered these 
pain medicines respectively out of the 248 records which were reviewed. As common as the 
symptom of pain was, this has not been reflected in or positively influenced the availability of 
morphine as the drug of choice for moderate to severe pain in palliative care. This unfortunate 
scenario is clearly shown in this study where the prescribed and administered morphine was 
still very low as highlighted above. The 2009 report on the global distribution of pain 
medication, especially morphine, shows Africa having only 0.8% of the share (47) of global 
morphine consumption. This study in Zimbabwe affirms that less morphine is prescribed and 
administered than would reasonably be expected to be required, given the disease burden and 
 “Aaah morphine is what those who are about to die 
get, and some of the doctors I have seen before told me 
it is a dangerous drug and one should not get used to 
it”. 
Exploring a patient’s opiophobia 
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prevalence of symptoms, especially pain. Figure 8 below supports this unfortunate scenario 
especially for Africa. The findings in terms of pain control together with the concerns raised on 
drug availability (discussed below) by the health workers resonates with Pettus’ statement in 
her article on reasons for drug policy reform (72). Pettus explained that “availability of 
controlled medicines must be commensurate with clinical need, with safe distribution and 
dispensing systems, to overcome the scandalously low consumption levels that for too long 
have been distorted by the war on drugs” (72) and the fact that opioid abuse affects availability 
(73). Issues to do with availability of palliative care drugs in general are further discussed later 
on in this write up looking commenting on the study findings. 
 
 
Figure 7: Worldwide distribution of morphine consumption in 2009 (Source: International 
Narcotics Control Board (47). 
 
  
This study’s findings on pain control showed the use of drugs like paracetamol, codeine 
phosphate, tramadol and morphine which are among the essential drugs for the different levels 
of pain. These analgesics used in pain management fall within the WHO analgesic step-ladder 
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and its components. WHO recommends palliative care analgesic approach of “by the mouth, by 
the clock, by the ladder and for the individual” (74) which was not explored here.   
Severe pain (pain scale of 7-10) is one of the most common palliative care symptoms 
encountered by patients with life-threatening illnesses and the pharmacological management 
with opioids can be influenced by the patient, family and health care worker’s attitudes. 
Opiophobia from the patients and their families is a common encounter among palliative care 
practitioners and is made worse when other team members in healthcare share the sentiment 
of fear or mistrust of the medication. The reduced uptake in opioid analgesics in this study 
could as well have been due to opiophobia amongst other possible reasons.   
In some cases, the patient records and health care workers indicated that severe pain in 
palliative care patients was managed using pethidine, which highlights the need for improved 
training especially on management of chronic pain associated with end-of-life care. In some 
cases, pethidine could have been prescribed for acute pain presentation; however, given the 
chronicity of most of the haematology and oncology conditions pethidine is inappropriate. 
Although EDLIZ says pethidine can be used for severe pain in patients who are allergic to 
morphine, there are many reasons why it should not be given in chronic pain; some of which 
are its short duration of action, no oral form, more anticholinergic effects, is neurotoxic and 
creates addiction (75). For example, sickle cell disease patients who often present in painful 
crisis, should have alternative pain management processes to avoid dependence on pethidine. 
This emphasizes the need to train the health care professionals in palliative care instead of just 
providing a list of medications (36).  Pain control is therefore multifaceted, requiring the 
knowledge of the medications to be given by the health workers, the availability of the drugs 
and accessibility by the beneficiaries.  
The use of combination drugs in pain management was reported by several health care workers 
and noted in the patient records. Pain control in palliative care using combination drugs like 
tramadol 37.5mg/paracetamol 325mg and acetaminophen 320mg/caffeine 32mg/ codeine 
phosphate 8mg/meprobamate 150mg was identified in both the health workers’ responses and 
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medical records. The South African study mentioned in the literature review showed that the 
use of combination drugs should not be used in palliative care due to the chronic nature of the 
symptoms especially pain which requires adjustments of doses on a regular basis (57). 
Combinations of simple analgesics certainly have a place in acute pain, especially nociceptive 
type but their use in chronic pain is discouraged, because of the frequency of drug interactions 
and adverse effects, particularly, paracetamol and codeine preparations as they are likely to 
lead to unwanted rebound effects such as sedation and impaired cognition (76).  
6.1.4 Managing other distressing symptoms 
Besides pain, there are other distressing palliative care symptoms as shown in the results 
section and these equally require proper pharmacological approach. Regarding patients with 
AIDS, there are now different findings due to the availability of ART and people living relatively 
healthier lives, however in the broader palliative care context cachexia is a syndrome which still 
presents with some of the distressing symptoms. One of the symptoms in the cachexia 
syndrome is weight loss, though its severity not quantified in this study it was mentioned by 
almost half of the health workers as one of the palliative care symptoms encountered and some 
of the patient records in the survey documented loss of weight. These findings affirm the fact 
that loss of weight is still a concern in palliative care. The number of patients documented in 
this study as having loss of weight was low in comparison to the total number of patient 
records. This symptom is often not listed when attending to patients even though some drugs 
have been seen to improve quality of life of cachexic patients. Corticosteroids for example 
dexamethasone 2-6 mg once a day have been shown to improve both anorexia and weakness in 
cancer patients (33).  
 
The patient records survey and the responses given by the health workers show that the health 
workers understand the management of palliative care symptoms with drugs, which is 
demonstrated by the correlation of their responses and the study results with the WHO 
symptoms and palliative care medicines list. This study showed that there are local variations 
and attention to detail is important, including all symptoms identified in the local area, as well 
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as the common ones that are from Potter’s list. The other symptoms identified were: 
palpitations, dizziness, dehydration, headache, loss of appetite, visual and hearing problems.  
6.2 Understanding symptom assessment 
 
The findings in this study show that most of the patients who require palliative care and pain 
relief do not get it for various reasons, which corresponds with the 2017 Lancet palliative care 
report for the developing countries. The results showed that there was a high palliative care 
symptom burden as elicited in the patient records and corresponding with the listed symptoms 
by the health workers. There was no systematic way of recording the symptoms, such as the 
use of an assessment tool; most of the patient records simply stated some symptom related to 
palliative care without reference to how that symptom was assessed. There was no 
standard/uniform format documented in the patient records for grading the pain or the other 
symptoms, although some health workers did mention some of the tools and resources they 
use. It is not certain therefore, whether and how health workers document their findings. These 
findings could be explained by the observation that in the “palliative care setting the patient 
population is often frail, has deteriorating health and has multiple symptoms” (77) which all 
influence getting the information from the patient. This supports the need for tools to act as a 
guide and to evaluate the care given and symptom management for the patient.  
6.3 Treatment and drug availability 
 
Palliative care drug availability emerged as a major theme in the responses given by the health 
workers and drug availability is an important factor in palliative care symptom management, 
despite the lack of documentation about why patients did not get certain drugs. In the 
questionnaire, there was no guideline or list of drugs for the health workers to rate the 
availability (figure 3 on results), because this was intentionally left open to allow the 
respondents to report the drugs they have available on the ground, reducing predetermining 
the response after seeing a list. The availability of the essential medicines for palliative care is 
influenced by the supply chain and the cost of the drugs, a factor raised by the health workers. 
Palliative care is recognized as a basic human right, so it is important that it is treated 
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adequately. However, the patient records showed that in some cases, the drugs administered 
to patients were lower than what was prescribed as has been already discussed under pain 
management above. There are several reasons why admitted patients can miss getting their 
drugs, including stock insufficiency, patients declining, being unfit to take the medication or 
being absent during the medication time. However, from this study only the stock insufficiency 
was documented and this can be interpreted as an emphasis to the problems to do with the 
availability of the drugs.  
Some of the prescribed drugs were out of stock, according to the drug chart and participants’ 
responses. All the drugs in this study were either in short supply or not available as shown by 
the reduced figures of what the patients eventually received. This highlights the health workers’ 
observation that drug supply is erratic, in short supply, very costly and not accessible to the 
patients. This shows that while the prescribers may do their part, the beneficiaries or the 
patients do not necessarily pharmacologically benefit from the care they are supposed to get in 
order to improve their quality of life due to factors to do with drug availability such as the 
supply and cost. 
The cost of drugs was highlighted in the evidence as a big challenge for drug availability at the 
hospital, and some of the recommendations raised to improve palliative care symptom 
management includes advocating for free drugs for palliative care, especially considering 
control of the symptoms is a basic human right. In 2009 a study to evaluate children’s palliative 
care service in Africa showed that the most valued service strengths were free drugs (78).  By 
enabling access to free drugs, developing nations may be able to better look after their most 
vulnerable inhabitants, however the cost effectiveness of such an approach needs continuous 
evaluation, and perhaps they will need to come up with a way of covering the costs of this. 
Opting for free drug supply will eventually lead to a more controlled palliative care symptom 
burden and hence improved quality of life for the patients. The patient records clearly revealed 
the gap between expectations and reality in terms of the drugs the patients received, and we 




6.4 Policy, health workers and drug use 
 
When considering the participants in the research study, it is worth noting that the doctors, 
nurses and other health workers were generally experienced practitioners. The fact that of the 
26 health workers (doctors and nurses) who participated in the study, more than half, 18 (69%) 
had more than 5 years of work experience leads to a conclusion that the responses obtained 
were from people who have had enough exposure to patients (especially those with life-
threatening illnesses) and therefore their responses when understanding their advocacy and 
use of drugs for treating palliative care symptoms need to be considered seriously.  The 
thematic analysis of health worker responses on their opinions of the pharmacological 
management of palliative care symptoms revealed a similar trend with findings, specifically 
from the Lancet commission 2018, British journal of haematology 2011 and the Lancet oncology 
2013 within LMIC (1-3, 6). This is an important finding in advocating and pushing for setting up 
the correct policies within the Zimbabwean context, as local findings correlate with similar 
evidence from other African situations. With all the supporting evidence from elsewhere and 
locally, the challenge is now to ensure the necessary action from all stakeholders concerned to 
implement the recommendations of these valued health workers.  
 
Health workers emphasised the importance of policy, which plays a big role, from the cost of 
drugs or the need for engaging some nurses in prescribing for palliative care patients. Policies 
act as guiding and control standards for the practice. A qualitative study on the impact of nurse 
prescribing by Bradly and Nolan in UK noted that “nurse prescribing has the potential to 
improve service-user care, enhance collaboration and widen discussions about medicines” (79). 
Policy makers must also come up with other ways of bridging the gap between identifying the 
palliative care symptom and addressing it as priority, this may involve reviewing who can 
prescribe drugs for symptom management. In Zimbabwe, there has been provision for nurses 
to prescribe in certain areas of practice, for example midwives prescribing pethidine in labour; 
in the palliative care context, efforts are underway with the relevant bodies to have nurses 
prescribe morphine for palliative care patients. The suggestions from the health workers in this 
study on nurse prescribing for palliative care within the African context needs to be followed up 
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using comparative findings from regions that have already embarked on nurse prescribing for 
some time, especially the developed world.  
 
Policy also influences how and when drugs are prescribed, as was indicated by participants of 
the study. Another area noted by the majority (57%) of the health workers was the use of 
references as an important guide in prescribing for palliative care symptoms. One of the 
sources mentioned was the EDLIZ. In support of providing reference lists to be used by 
prescribers, the national taskforce on palliative care in Zimbabwe is addressing the essential 
palliative care drug list inclusion into the EDLIZ so as to provide an easily accessible national 
guideline for the health workers. While the essential medicines concept was endorsed as way 
back as 1977 (80), the fact that patients still cannot get the essential medicines due to several 
factors is a cause for strong advocacy on behalf of the patients by the clinical team, the patients 
themselves and their families.  
When considering lists of essential medications, policy and norms also play a role in the 
management of symptoms. This study made the assumption that the health workers working in 
haematology and oncology departments knew what was meant by palliative care medications 
as they take care of patients with life threatening illnesses, hence the questionnaire left it open, 
as discussed previously. However, the findings revealed a gap in the palliative care knowledge 
of the workers, and a checklist using the essential medicines for palliative care symptom 
management could have guided the responses. WHO defines “essential medicines as those 
which satisfy the primary health care needs of the population (81) and further states that 
twenty-one symptoms were identified as the most common in palliative care, with 33 
medicines being included in the IAHPC List of Essential Medicines for Palliative Care” (82).  
Some of these were highlighted by the health workers in this study, but it is noteworthy that 
the lists of medications given by the health workers did not include all the drugs listed in the 
WHO essential drug list for palliative care (2013) or the EDLIZ (2015) chapter on pain and care 
of the terminally ill. It shows therefore that the WHO, EDLIZ and any other lists of 
recommended essential medications are guidelines that the clinicians use or may not use, but 
the reasoning for this was not explored in this study. However, the gap in the list of essential 
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palliative care medications in Zimbabwe’s essential drug list is a noted area which is being 
addressed by the EDLIZ committee. A country’s essential drug list is a useful guide especially in 
the primary health care setup where palliative care has to be implemented in the care of all the 
patients with chronic illnesses some of which pose serious challenges in the daily activities of 
the patients. 
It is worth noting that this study was conducted at a tertiary institution in departments which 
were assumed to have more palliative care patients, but ultimately the research highlighted 
particular gaps in knowledge and practice; one can assume that at lower levels of care or in less 
specialized contexts, there is likely a similar picture. This needs to be proved by doing similar 
studies in clinics and other smaller health facilities. However, the point coming out here is the 
need to revisit policies which have a bearing on public health as they can positively or 
negatively have an impact on the population. If palliative care has to be provided at primary 
care level which is usually the first and last port of call for patients, it therefore calls for the 
need to have prescribers for essential medicines especially for morphine which is the 
recommended drug for moderate to severe pain in palliative care at all levels.   
 
6.4.1 Policy and training for health professionals 
 
Education and training of health professionals on palliative care symptoms and their 
management was highlighted by the participants as a prerequisite to improve palliative care. 
Ongoing training for health workers on history taking, physical examination and symptom 
assessment for palliative care patients is necessary as well as the drugs in use. Focussing on the 
pharmacological management of symptoms includes mentorship on the use of treatment 
protocols since these have proven effective interventions to promote rational prescribing (83). 
The WHO public health strategy, which was published after wide consultation and research 
includes education as one of the main strategies for the successful implementation of palliative 
care programs (84). A study by Reddy and colleagues concluded that “Haematology and 
Medical Oncology (HMO) fellows reported PC rotation improved their attitudes and knowledge 
in all PC domains” ((85), supporting the need for education and training in palliative care at all 
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levels. Health workers must therefore be trained to be confident to use the medication 
available to manage their patients’ symptoms.  
As indicated in the section of the discussion about the management of pain as a symptom, this 
research indicates the opportunity for improving quality of life for palliative care patients 
through improved training and understanding of global and local policy and recommendations. 
Therefore, there is need for ongoing update of health workers’ knowledge in-order to keep up 
to the recommended guidelines for the recommended palliative care drugs for example 
exploring why combination drugs are discouraged in managing chronic pain.  Education and 
training of the patient, family and health workers on the pharmacological approach of palliative 
care symptoms would help to increase demand for good symptom control as part of palliative 
care 
 
6.5 Role of demographics: knock-on effect of improving palliative care symptom 
management 
 
Considering the key focus of this study on symptoms and management, not all information 
within the patient records is within the scope of this study, but it may have some impact on the 
findings reported. For example, one note on demographics is that the female patient 149 (60%) 
predominance over the number of male patients 98 (40%) reviewed on records could most 
likely explain why cervical cancer was the predominant diagnosis, however these findings are 
not within the scope of this study and therefore will not be analysed or discussed further here. 
Some of the information discovered in the review of patient records, such as the age 
distribution and the patients’ diagnoses, will be taken up by the researcher in further studies as 
they contribute to the knowledge base of palliative care.   
 
The African context of this research is significant because of the role of symptom management 
for maintaining an active workforce struggling with life-threatening and life-limiting illnesses. In 
terms of the relevance of this research to other contexts, the patient demographics from this 
study has shown that in the African setting, palliative care is not only for the elderly as 
54 
 
evidenced by the big part of the records being for the 34-60-year age group. These findings 
correlate with a study which was done at a hospital in Malawi which also showed that the 
palliative care population is young, especially in patients with HIV related diagnoses (86). This is 
the working age population, and the amount of time given for work by those with life-
threatening illnesses will be determined by the proper control of the palliative care symptoms 
they present with. This means that a good approach to managing palliative care symptoms has 
a knock-on effect on various aspects, including the country’s economy.  
 
6.6 Impact of findings in the Zimbabwean context        
The impact of this study for Zimbabwe is that a holistic approach to palliative care in addressing 
the patient’s needs should be emphasised as this not only engages the patient and the family 
but usually more than one health care professional (87). With the increasing need to integrate 
palliative care into the health care system in most countries, continuous evidence-based 
training of the recommended pharmacological approach for palliative care symptoms is 
necessary for health care workers at all levels in Zimbabwe. Good care for palliative care 
patients requires a holistic approach delivered by a multidisciplinary team, which was reflected 
and highlighted by the health workers in this study. The need for a multidisciplinary approach is 
felt more when palliative sedation is considered as this has strong patient and family factors 
which requires team deliberations to come to an agreement (54). This collaboration is often 
difficult as few doctors have had adequate palliative care training. Hence study brought out the 
need for multidisciplinary team approach in palliative care, this is however an area that perhaps 
needs further exploring within the Zimbabwean context putting into consideration issues which 
are specific for Zimbabwe. 
This study showed that palliative care provision is not well integrated into the health care 
system of Zimbabwe, as evidenced by the findings on the pharmacological management of 
palliative care symptoms from one of the main tertiary hospitals in the country. The health 
workers emphasized some of the important gaps requiring attention in order to integrate 
palliative care, including drug availability, symptom assessment and recording and adequate 
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training for health workers.  These key factors that fall under the public health strategy on 
palliative care were highlighted from the findings and resonate well with Lamas and 
Rosenbaum’s statement in 2012 that “while the global burden of cancer and other non-
communicable diseases grows, lack of funding remains an impediment to the dissemination of 
effective treatment” (88). Essential palliative care medicines are still not readily available, not 
accessible and not affordable to the public in Zimbabwe. Context-specific policies relating to the 







1. The limitations of the study include the fact that it only focused on selected health 
workers and on patient records from the oncology and haematology patients of a 
selected hospital in Harare. 
2. Questionnaire tool validity and reliability was compromised by the fact that the 
participants had to fill in the responses which were then further ascribed by the 
researcher, interpretation of what was exactly meant could have been somehow 
distorted given that certain words for example “method” would be interpreted 
differently, thereby coming up with conclusions not well supported by the data 
obtained. 
3. Assumption that the participants would be going with the flow of questions linking them 
compromised the validity and reliability of some of the questions which were closed for 
example the question “are palliative care symptoms adequately controlled” and the 
response was a yes or no tick box, however this was followed up in the next question.  
4. Patient records were sometimes incomplete, limiting the value of that record for data 
collection.  






8.  Recommendations 
1. A similar study can be undertaken involving asking patients with life-threatening 
illnesses or their families, their feedback when given appropriate pharmacological 
interventions for their palliative care symptoms in order to assess their quality of life 
before and after. 
2. The education and training committee for the Zimbabwe palliative care integration 
taskforce should note the gap in the knowledge observed in this study and highlight 
these areas in the ongoing in-service training, and the institutions of higher learning 
embarking on palliative care training should cover this within their curricula. 
3. Issues of policy regarding availability of palliative care drugs at no cost or minimal cost 
to be taken on through relevant ministry of health officials and active advocacy by 
patients and health workers. 
4. The IAHPC has developed the List of Essential Medicines for Palliative Care and it is 
available for use by all (82), this is an opportunity for all countries like Zimbabwe with 
supply problem to use. 
5. Conduct a quantitative study to test the generated hypothesis that clinician prescribing 
in Zimbabwe for palliative care symptoms is influenced by a number of factors, the 2 
commonest being palliative care drug availability and palliative care knowledge of the 
prescribers. 
6. Follow up studies are important as they show the value of the previous study and 
promote uptake of the recommendations to inform good practice. In addition, this study 
was limited to a tertiary hospital context, and less-resourced settings may benefit from 
similar studies to explore if they suffer from similar gaps in knowledge and practice. 
7. The guidelines operationalize the ideas and intentions therefore there is need for 






This study focusses on the pharmacological management of palliative care symptoms in Africa 
and particularly in Zimbabwe by investigating practices and attitudes in one big institution in 
Harare. PGH is an important provider of treatment and quality of life for patients in Zimbabwe 
with life threatening illness.  
 
The commonest symptom observed was pain and the findings showed that its management is 
generally aligned with the WHO guidelines, though with some variations, for example, the use 
of combination pain medications and other drugs not encouraged in patients with chronic pain. 
The study demonstrated a gap, however, in that doses of analgesic medication prescribed and 
administered were below the threshold of what would usually be required and possibly sub-
therapeutic. This corresponds to experience and data from other African and LMIC countries.  
 
Analysis of the responses of the health workers, which was supported in the patient record 
analysis identified a further gap in clinical practice which was a lack of use of symptom 
assessment tools to guide the comprehensive approach to care of patients with life threatening 
illness and a high symptom burden. Certain symptoms which may be amenable to management 
were not recorded or mentioned in the survey responses. The study opened up opportunities 
for future research in applying validated tools like IPOS or ESAS to the burden of symptoms.  
Analysis of the responses of the health workers in the survey showed that nurse prescribing of 
some palliative care medications may address the pressing need for better symptom 
management in these patients.  
Education and training of all health workers would be required to ensure comprehensive 
assessment using symptom assessment tools and safe prescription by all health workers, 
including nurse prescribing as suggested above.  Advocacy plays an important role in palliative 
care provision, particularly to ensure the availability of palliative care medications and the 
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development of policy to support the required education for comprehensive palliative care, 
nurse prescription and contribute to the public health approach to palliative care provision. 
This research project has explored the use and availability of palliative care medications and 
related factors providing evidence to improve practice, improve the quality of palliative care 
delivery and develop policy for the future implementation of these measures. This quality 
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Appendix 1: Information Sheet 
Title of the research: The pharmacological management of palliative care symptoms in 
hematology and oncology patients at Parirenyatwa group of hospitals (PGH) in Harare 
Zimbabwe. 
Introduction 
Thank you for giving your time to hear about this study. This information sheet tells you about 
the study that you may wish to take part in. You may have some further questions to help you 
decide whether you want to take part. You can ask any further questions from the researcher, 
supervisor or co-supervisor using the telephone numbers at the end.  
Thank you for thinking about whether you want to take part. Please take your time to make a 
decision.  
The study findings will be used to support the Zimbabwe ministry of health’s current efforts to 
integrate Palliative Care into the country’s health system delivery. 
What is the purpose of the study? 
The aim of this study is to determine the drugs used in the management of palliative care 
symptoms in hematology and oncology patients at PGH thereby identifying gaps or areas of 
strength using the WHO essential drug list for palliative care. 
Do I have to take part? 
No, you do not have to take part. If you do agree to take part, you are free to withdraw from 
answering the questionnaire at any time without giving any reason. If you do agree to take part, 
you will be asked to sign a consent form, which shows that you have agreed to do so. You can 
take some time to think about whether you would like to take part.  
How is the study conducted?  
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After you have read through this information sheet and signed your consent to take part in the 
study you will get a questionnaire from the research assistant which you have to fill in the 
responses and give back to the research assistant. Further information will be obtained from 
patient records at PGH.  
What do we expect from you?  
You are asked to fill in the questionnaire given to you. This will take about 10minutes of your 
time. Your participation is voluntary and you can decline to answer certain questions or end 
your participation at will. 
What happens if you do not wish to participate in this study?  
Participation in this study is voluntary; therefore, if you decide not to participate you can 
withdraw without signing anything else. You are not obliged to explain why you do not want to 
participate but if you want to explain why you may do so.  
What happens to your data?  
The questionnaires will use number codes, so your name will not appear. The information on 
the questionnaires will be transferred into database which will not trace any of the information 
to you but will be anonymous.  
Is there anything else you want to know?  
For any questions or clarifications about this study you can contact the researcher and/or co-
supervisor on the details given below. Kind regards,  
Researcher: Agnes Chipo Tererai, +263782321202, email: atererai@gmail.com 
Supervisor: Dr Alan Barnard, UCT, +27835642939 
Co-supervisor: Dr N Tsikai, UZ, +263772275888 
If you have any questions about your human rights or any ethical issues please contact: 
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UCT Research Ethics Committee:  
Mrs. Lamees Emjedi Research Ethics Committee E 52 Room 24, Old Main Building, Groote 
Schuur Hospital, Observatory Telephone:  021 406 6338 
 
Consent form  
 
1. I confirm that I have read and understand the information sheet and have had the opportunity to 
ask questions. 
 
2. I understand that my participation is voluntary and I am free to withdraw at any time, without 
giving a reason, without my care being affected. 
 
 
3. I agree to take part in the above study. 
Name ________________________________    
 
Signature _____________________________   Date ________________ 
 
Researcher:  Signature __________________   Date: _______________   
   
Witness:  Name  
(from clinical team or family member) 
 






Appendix 2: Questionnaire for health workers and Patient records survey 
Topic: The pharmacological management of palliative care symptoms in hematology and 
oncology patients at Parirenyatwa group of hospitals (PGH) in Harare Zimbabwe 
Please fill in all that applies to your level! 
1. What is your profession, tick applicable 
Specialist Dr    Senior Doctor      Junior Doctor  Registrar (MMed) 
Senior Nurse    Oncology Nurse  Student Nurse   Pharmacist 
Other…………………….. 
2. How many years have you been practicing: Tick applicable 
     <5years     5-10years         >10years 
3. Do you use a symptom assessment method/tool?   YES   NO 
4. If Yes to above, which method/tool do you use?........................................................... 
5. Number the Palliative care symptoms you manage (use list below or add your own) 
according to the most common presenting starting from 1 as most common  
Pain    Anorexia   Constipation 
Weakness   Dyspnea   Nausea 
Neuropsychiatric  Tiredness   Weight Loss 
Low mood   Vomiting   Dry Mouth 
Cough    Dermatological  Urinary 
Anxiety   Edema    Sleep problems 
Loose stool   Dyspepsia   Numbness/tingling 
Dysphagia   Hemorrhage   Early satiety 
Sweating   Hiccoughs   Taste Change 
Other…………………………………………………………………………………………………………………. 
6. Do you prescribe PC medications:                    YES           NO 
7. Do you consult EDLIZ when prescribing PC drugs:           YES                        NO       
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8. What other sources do you consult when prescribing PC drugs……………………………….. 
9. Do you dispense medications/drugs     YES           NO       
10. If yes to 9 above, how do you rate your Palliative Care drug stocks? Tick applicable: 
   Inadequate     Adequate 
11. Please list the essential palliative care drugs in your stocks under the descriptions below: 
Never    Sometimes    Always 
………………………………  …………………………  …………………………………… 
………………………………  …………………………  ……………………………………. 
………………………………  …………………………  ……………………………………. 
……………………………...  …………………………  ……………………………………. 
………………………………  …………………………  ……………………………………. 
………………………………  …………………………..  ……………………………………. 
………………………………  …………………………..  ………………………………...... 
    
12. For Pain list the drugs you use? 
Level of Pain    Drugs used     
Mild Pain ……………………………………………………………………………………………………….  
Moderate Pain………………………………………………………………………………………………..  
Severe Pain……………………………………………………………………………………………………..  
13. List the drugs you use for morphine side effects 
Morphine Side Effect  Drugs      
…………………………..  ……………………………………………………………………………  
…………………………..  …….................................................……………............  
……………………………  ……………………………................................................... 
…………………………….  ……………………………………………………………………………..  
…………………………….  ………………………………………………………………………………  
14. Tick Adjuvant/co-analgesic drugs in Palliative Care used at your department  
Drug          
     Prednisolone                                           Carbamazepine    
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     Dexamethasone             
     Amitriptyline 
     Gabapentin 
     Pregabalin 
     Other……………. 
15. Besides pain please list other 5 common PC symptoms you manage/see and the drugs 
you use? 








16. From your experience, are palliative care symptoms adequately controlled for your 
patients in terms of drugs used?        Yes                 No 














19. Give 2 or 3 recommendations to improve pharmacological management of palliative 







20. Please write below any other comments you may have concerning pharmacological 














4. Palliative care symptoms documented 
5. Palliative care drugs prescribed 
6. Palliative care drugs administered 
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